Oramed Pharmaceuticals Inc.
DE ˙ DB ˙ US68403P2039
3,26 € ↑0,10 (3,16%)
2026-06-04
AKTIENPREIS
SecurityDE:OJU1 / Oramed Pharmaceuticals Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership8,989 shares
Latest Disclosed Value $ 30,563
Citigroup Inc ownership in OJU1 / Oramed Pharmaceuticals Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 8,989 shares of Oramed Pharmaceuticals Inc. (DE:OJU1) valued at $25,394 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 0 shares of Oramed Pharmaceuticals Inc.. The current value of the position is $29,349 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 8,989 8,989 31 0.0000
2026-02-13 2025-12-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 0 -4 -100.00 0 0.0000
2025-11-10 2025-09-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 4 4 0 0.0000
2024-02-09 2023-12-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 0 -41,471 -100.00 0 -100.00
2023-12-06 2023-09-30 13F/A-1 ORAMED PHARMACEUTICALS COM NEW 68403P203 41,471 4,027 10.75 108 -19.40 0.0001
2023-11-09 2023-09-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 41,471 4,027 108 0.0000
2023-08-10 2023-06-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 37,444 12,388 49.44 134 148.15 0.0001
2023-05-11 2023-03-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 25,056 -40,834 -61.97 55 -93.18 0.0000
2023-02-09 2022-12-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 65,890 35,246 115.02 793 297.99 0.0006
2022-11-10 2022-09-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 30,644 27,061 755.26 199 1,143.75 0.0001
2022-08-10 2022-06-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 3,583 1,138 46.54 16 -23.81 0.0000
2022-05-12 2022-03-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 2,445 -5,839 -70.49 21 -82.20 0.0000
2022-02-10 2021-12-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 8,284 4,839 140.46 118 55.26 0.0001
2021-11-10 2021-09-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 3,445 74 2.20 76 68.89 0.0000
2021-08-10 2021-06-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 3,371 -621 -15.56 45 9.76 0.0000
2021-05-13 2021-03-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 3,992 -4,708 -54.11 41 10.81 0.0000
2021-02-11 2020-12-31 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 8,700 0 0.00 37 60.87 0.0000
2020-11-12 2020-09-30 13F ORAMED PHARMACEUTICALS COM NEW 68403P203 8,700 0 0.00 23 -25.81 0.0000
2020-08-12 2020-06-30 13F ORAMED PHARM COM NEW 68403P203 8,700 0 0.00 31 19.23 0.0000
2020-05-12 2020-03-31 13F ORAMED PHARM COM NEW 68403P203 8,700 -800 -8.42 26 -46.94 0.0000
2020-02-12 2019-12-31 13F ORAMED PHARM COM NEW 68403P203 9,500 0 0.00 49 63.33 0.0000
2019-11-08 2019-09-30 13F ORAMED PHARM COM NEW 68403P203 9,500 0 0.00 30 -11.76 0.0000
2019-08-12 2019-06-30 13F ORAMED PHARM COM NEW 68403P203 9,500 0 0.00 34 -2.86 0.0000
2019-05-13 2019-03-31 13F ORAMED PHARM COM NEW 68403P203 9,500 0 0.00 35 20.69 0.0000
2019-02-12 2018-12-31 13F ORAMED PHARM COM NEW 68403P203 9,500 0 0.00 29 -36.96 0.0000
2018-11-13 2018-09-30 13F ORAMED PHARM COM NEW 68403P203 9,500 2,100 28.38 46 -16.36 0.0000
2018-08-10 2018-06-30 13F ORAMED PHARM COM NEW 68403P203 7,400 855 13.06 55 27.91 0.0001
2018-05-11 2018-03-31 13F ORAMED PHARM COM NEW 68403P203 6,545 6,545 43 0.0000
2016-05-13 2016-03-31 13F ORAMED PHARM COM NEW 68403P203 0 -73 -100.00 0 -100.00
2016-02-12 2015-12-31 13F ORAMED PHARM COM NEW 68403P203 73 73 0.00 1 0.0000
2015-08-13 2015-06-30 13F ORAMED PHARM COM NEW 68403P203 0 -115 -100.00 0 0.0000
2015-05-14 2015-03-31 13F ORAMED PHARM COM NEW 68403P203 115 115 0.00 0 0.0000
2015-02-17 2014-12-31 13F ORAMED PHARM COM NEW 68403P203 0 -3,000 -100.00 0 -100.00
2014-11-14 2014-09-30 13F ORAMED PHARM COM NEW 68403P203 3,000 1,000 50.00 24 26.32 0.0000
2014-08-14 2014-06-30 13F ORAMED PHARM COM NEW 68403P203 2,000 1,000 100.00 19 58.33 0.0000
2014-05-15 2014-03-31 13F ORAMED PHARM COM NEW 68403P203 1,000 700 233.33 12 140.00 0.0000
2014-02-14 2013-12-31 13F ORAMED PHARM COM NEW 68403P203 300 300 5 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.